Relevance of absorption rate and lag time to the onset of action in migraine

Clinical Pharmacokinetics

Volumn 47, Issue 2, 2008, Pages 139-146

  Maas, Hugo J ^a   Spruit, Marc A H ^a   Danhof, Meindert ^a   Della Pasqua, Oscar E ^a,b  

^a LEIDEN UNIVERSITY   (Netherlands)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Migraine, treatment; Pharmacokinetic modelling; Sumatriptan, pharmacokinetics

Indexed keywords

SUMATRIPTAN; TRIPTAN DERIVATIVE;

ARTICLE; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG DISPOSITION; DRUG FORMULATION; HUMAN; MAJOR CLINICAL STUDY; MIGRAINE; PRIORITY JOURNAL; PROBABILITY; SIMULATION; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTESTINAL ABSORPTION; MARKOV CHAINS; MIGRAINE DISORDERS; MODELS, BIOLOGICAL; RECEPTOR, SEROTONIN, 5-HT1B; SEROTONIN AGONISTS; SOFTWARE; SUMATRIPTAN; TIME FACTORS; TREATMENT OUTCOME;

EID: 38149013952     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200847020-00007     Document Type: Article

References (33)

1. McCrory DC, Gray RN. Oral sumatriptan for acute migraine. Cochrane Database Syst Rev 2003; (3): CD002915
2. Dodick DW. Triptan nonresponder studies: implications for clinical practice. Headache 2005; 45 (2): 156-62
3. Walls C, Lewis A, Bullman J, et al. Pharmacokinetic profile of a new form of sumatriptan tablets in healthy volunteers. Curr Med Res Opin 2004; 20 (6): 803-9
4. Sheftell FD, Dahlof CG, Brandes JL, et al. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets. Clin Ther 2005; 27 (4): 407-17
5. Ahrens SP, Farmer MV, Williams DL, et al. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group. Cephalalgia 1999; 19 (5): 525-30
6. Stockli HR, Sword A. Zolmitriptan as fast-melt tablet in the acute treatment of patients with migraine attacks: the ZORO study. Schweiz Rundsch Med Prax 2003; 92 (9): 379-89
7. Olson NZ, Otero AM, Marrero I, et al. Onset of analgesia for liquigel ibuprofen 400 mg, acetaminophen 1000 mg, ketoprofen 25 mg, and placebo in the treatment of postoperative dental pain. J Clin Pharmacol 2001; 41 (11): 1238-47
8. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 2004; 55 (1): 19-26
9. Hu XH, Raskin NH, Cowan R, et al. Treatment of migraine with rizatriptan: when to take the medication. Headache 2002; 42 (1): 16-20
10. Loder E. Menstrual migraine: timing is everything. Neurology 2004; 63 (2): 202-3
11. Maas HJ, Danhof M, Della Pasqua OE. Prediction of headache response in migraine treatment. Cephalalgia 2006; 26 (4): 416-22
12. Troconiz IF, Wolters JM, Tillmann C, et al. Modelling the anti-migraine effects of BIBN 4096 BS: a new calcitonin gene-related peptide receptor antagonist. Clin Pharmacokinet 2006; 45 (7): 715-28
13. Cosson VF, Fuseau E. Mixed effect modeling of sumatriptan pharmacokinetics during drug development: II. From healthy subjects to phase 2 dose ranging in patients. J Pharmacokinet Biopharm 1999; 27 (2): 149-71
14. Box GEP, Cox DR. An analysis of transformations. J R Stat Soc Series B-Stat Methodol 1964; 26 (2): 211-52
15. Rabiner LR. A tutorial on hidden Markov models and selected applications in speech recognition. Proc IEEE 1989; 77 (2): 257-86
16. Maas HJ, Danhof M, Della Pasqua, et al. A model-based approach to treatment comparison in acute migraine. Br J Clin Pharmacol 2006; 62 (5): 591-600
17. Holford NH, Sheiner LB. Pharmacokinetic and pharmacodynamic modeling in vivo. CRC Crit Rev Bioeng 1981; 5 (4): 273-322
18. Tfelt-Hansen P, Block G, Dahlof C, et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000; 20 (9): 765-86
19. Bureau A, Hughes JP, Shiboski SC. An S-Plus implementation of hidden Markov models in continuous time. J Computat Graphical Stat 2000; 9 (4): 621-32
20. Anisimov VV, Maas HJ, Danhof M, et al. Analysis of responses in migraine modelling using hidden Markov models. Stat Med 2007; 26 (22): 4163-78
21. Edmeads J. Defining response in migraine: which endpoints are important? Eur Neurol 2005; 53 Suppl. 1: 22-8
22. Lanteri-Minet M. What do patients want from their acute migraine therapy? Eur Neurol 2005; 53 Suppl. 1: 3-9
23. Mondell BE. A review of the effects of almotriptan and other triptans on clinical trial outcomes that are meaningful to patients with migraine. Clin Ther 2003; 25 (2): 331-41
24. Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache 2002; 42 Suppl. 1: 3-9
25. Davies GM, Santanello N, Lipton R. Determinants of patient satisfaction with migraine therapy. Cephalalgia 2000; 20 (6): 554-60
26. Moschiano F, D'Amico D, Allais G, et al. Early triptan intervention in migraine: an overview. Neurol Sci 2005; 26 Suppl. 2: s108-10
27. Rapoport AM, Bigal ME, Tepper SJ, et al. Intranasal medications for the treatment of migraine and cluster headache. CNS Drugs 2004; 18 (10): 671-85
28. Duquesnoy C, Mamet JP, Sumner D, et al. Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration. Eur J Pharm Sci 1998; 6 (2): 99-104
29. Oldman AD, Smith LA, McQuay HJ, et al. Pharmacological treatments for acute migraine: quantitative systematic review. Pain 2002; 97 (3): 247-57
30. Volans GN. Migraine and drug absorption. Clin Pharmacokinet 1978; 3 (4): 313-8
31. Boyle R, Behan PO, Sutton JA. A correlation between severity of migraine and delayed gastric emptying measured by an epigastric impedance method. Br J Clin Pharmacol 1990; 30 (3): 405-9
32. Cutler NR, Hussey EK, Sramek JJ. Oral sumatriptan in pharmacokinetics in the migrainous state. Cephalalgia 1991; 11 Suppl. 11: 222-3
33. Hussey EK, Donn KH, Busch MA, et al. Pharmacokinetics of oral sumatriptan in migraine patients during an attack and while pain free [abstract no. PI-46]. Clin Pharmacol Ther 1991; 49: 46